Compugen Company Profile (NASDAQ:CGEN)

About Compugen

Compugen logoCompugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology. The Company's therapeutic proteins for immunology include CGEN-15001T, CGEN-15022, CGEN-15029, CGEN-15049 and CGEN-15092, which are based on B7/CD28-like immune checkpoint candidates. It offers various infrastructure platforms, which include LEADS, MED and LINKS, which integrates its scientific understandings and predictive models. It offers various target discovery platforms, which include Antibody-Drug Conjugate Cancer Therapy Discovery Platform, Other Discovery Approaches for Immunomodulatory Proteins and Biomarker Discovery Approaches.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CGEN
  • CUSIP:
Key Metrics:
  • Previous Close: $4.40
  • 50 Day Moving Average: $4.73
  • 200 Day Moving Average: $5.90
  • 52-Week Range: $4.28 - $7.57
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.43
  • P/E Growth: 0.00
  • Market Cap: $219.86M
  • Outstanding Shares: 51,044,000
  • Beta: 1.18
Profitability:
  • Net Margins: -261.77%
  • Return on Equity: -29.33%
  • Return on Assets: -26.61%
Debt:
  • Current Ratio: 14.91%
  • Quick Ratio: 14.91%
Additional Links:
Companies Related to Compugen:

Analyst Ratings

Consensus Ratings for Compugen (NASDAQ:CGEN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (179.07% upside)

Analysts' Ratings History for Compugen (NASDAQ:CGEN)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017FBR & CoReiterated RatingBuy$14.00View Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$14.00 -> $11.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$14.00 -> $11.00View Rating Details
2/11/2016Jefferies Group LLCReiterated RatingBuy$11.00 -> $9.00View Rating Details
2/1/2016Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
8/5/2015MLV & Co.Reiterated RatingBuy$14.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Compugen (NASDAQ:CGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2017Q416($0.17)($0.17)ViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)ViewN/AView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$1.15 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.80 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.48 millionViewN/AView Earnings Details
2/10/2015Q414($0.11)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.11)($0.05)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.10)($0.04)$0.16 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.13 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.11 million$1.60 millionViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Compugen (NASDAQ:CGEN)
Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.15)($0.13)($0.14)
Q2 20161($0.17)($0.17)($0.17)
Q3 20161($0.13)($0.13)($0.13)
Q4 20161($0.15)($0.15)($0.15)
Q1 20172($0.18)($0.17)($0.18)
Q2 20172($0.17)($0.17)($0.17)
Q3 20172($0.18)($0.17)($0.18)
Q4 20172($0.17)($0.08)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Compugen (NASDAQ:CGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Compugen (NASDAQ:CGEN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Compugen (NASDAQ:CGEN)
DateHeadline
News IconTrading Radar: Checking Technicals for Compugen Ltd (CGEN) - Davidson Register (NASDAQ:CGEN)
davidsonregister.com - February 24 at 9:25 PM
finance.yahoo.com logoCOMPUGEN LTD Financials (NASDAQ:CGEN)
finance.yahoo.com - February 22 at 4:24 PM
us.rd.yahoo.com logoCompugen Reports Fourth Quarter and Calendar Year 2016 Results (NASDAQ:CGEN)
us.rd.yahoo.com - February 16 at 9:30 AM
sg.finance.yahoo.com logoCompugen reports 4Q loss (NASDAQ:CGEN)
sg.finance.yahoo.com - February 16 at 9:30 AM
News IconCompugen Ltd. NASDAQ:CGEN Volatility at Extreme Levels - Aiken Advocate (NASDAQ:CGEN)
aikenadvocate.com - February 13 at 9:56 PM
nasdaq.com logoFNY Managed Accounts LLC Buys Tesla, St Jude Medical, SPDR S&P 500, Sells LinkedIn, NXP ... (NASDAQ:CGEN)
www.nasdaq.com - February 9 at 9:38 PM
News IconTechnical Toolbox: Investor Focus on Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - February 4 at 2:33 AM
News IconSignal Watch: Checking the Numbers for Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - February 2 at 9:33 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Compugen Ltd. (NASDAQ:CGEN)? - Wall Street Beacon (NASDAQ:CGEN)
wsbeacon.com - January 31 at 4:41 PM
News IconWhat are the Levels Showing for Shares of Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - January 31 at 4:41 PM
finance.yahoo.com logoCompugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST (NASDAQ:CGEN)
finance.yahoo.com - January 30 at 5:00 PM
News IconTicker Tracker: Looking at Compugen Ltd. (CGEN) - Rives Journal (NASDAQ:CGEN)
rivesjournal.com - January 28 at 4:23 PM
News IconTechnical Action Update on Shares of Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - January 26 at 10:11 PM
News IconEarnings in Full Force, Analysts Take Aim at Compugen Ltd. (NASDAQ:CGEN) - Wall Street Beacon (NASDAQ:CGEN)
wsbeacon.com - January 26 at 5:11 PM
News IconInvestor Focus on Shares of Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - January 22 at 4:16 PM
News IconTrading Insight: Taking a Look at Levels for Compugen Ltd. (CGEN) - Rives Journal (NASDAQ:CGEN)
rivesjournal.com - January 21 at 4:18 PM
News IconSorting Out the Technicals on Shares of Compugen Ltd. (CGEN) - Sherwood Daily (NASDAQ:CGEN)
sherwooddaily.com - January 20 at 3:33 AM
News IconWill The Needle Move For Compugen Ltd. (NASDAQ:CGEN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:CGEN)
wsbeacon.com - January 18 at 3:41 PM
News IconCompugen Ltd CGEN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CGEN)
www.bioportfolio.com - January 15 at 2:25 AM
realistinvestor.com logoCompugen Ltd. (NASDAQ:CGEN) EPS Estimate At $-0.15 - RealistInvestor.com (NASDAQ:CGEN)
www.realistinvestor.com - January 12 at 4:34 PM
investornewswire.com logoSentiments And Ratings Alert: Compugen Ltd. (NASDAQ:CGEN) - Investor Newswire (NASDAQ:CGEN)
www.investornewswire.com - January 6 at 4:39 PM
streetinsider.com logoCompugen (CGEN) Says CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity (NASDAQ:CGEN)
www.streetinsider.com - January 4 at 5:18 PM
reuters.com logoBRIEF-Compugen says disclosed animal model results demonstrating restoration of immune tolerance by cgen-15001 (NASDAQ:CGEN)
www.reuters.com - January 4 at 5:18 PM
us.rd.yahoo.com logoCompugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity (NASDAQ:CGEN)
us.rd.yahoo.com - January 4 at 5:18 PM
publicnow.com logoCompugen’s CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity (NASDAQ:CGEN)
www.publicnow.com - January 4 at 5:18 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Compugen Ltd. (NASDAQ:CGEN) - Prospect Journal (NASDAQ:CGEN)
prospectjournal.com - January 3 at 12:08 PM
nasdaq.com logoWhat Makes Compugen Ltd. (CGEN) a Strong Sell? - Nasdaq (NASDAQ:CGEN)
www.nasdaq.com - December 22 at 4:24 PM
News IconTrading Focus: Eye on Shares of Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - December 17 at 9:27 PM
News IconTrading Radar: Checking Technicals for Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - December 13 at 9:57 PM
capitalcube.com logoCompugen Ltd. – Value Analysis (NASDAQ:CGEN) : December 13, 2016 (NASDAQ:CGEN)
www.capitalcube.com - December 13 at 4:54 PM
News IconTop Stock With Upside & Growth Potential: Compugen Ltd. (NASDAQ:CGEN) - Prospect Journal (NASDAQ:CGEN)
prospectjournal.com - December 13 at 6:17 AM
capitalcube.com logoCompugen Ltd. breached its 50 day moving average in a Bullish Manner : CGEN-US : December 12, 2016 (NASDAQ:CGEN)
www.capitalcube.com - December 12 at 12:33 PM
News IconStock Tracker: Trend Analysis on Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - December 11 at 4:00 PM
prnewswire.com logoCompugen Announces Key Highlights from R&D Day - PR Newswire - PR Newswire (press release) (NASDAQ:CGEN)
www.prnewswire.com - December 8 at 5:03 PM
prnewswire.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting ... - PR Newswire (press release) (NASDAQ:CGEN)
www.prnewswire.com - December 8 at 5:03 PM
seekingalpha.com logoCompugen announces key highlights from R&D day - Seeking Alpha - Seeking Alpha (NASDAQ:CGEN)
seekingalpha.com - December 8 at 5:03 PM
us.rd.yahoo.com logoCompugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint (NASDAQ:CGEN)
us.rd.yahoo.com - December 7 at 4:54 PM
us.rd.yahoo.com logo7:26 am Compugen discusses data demonstrating that the CGEN-15029/PVRIG immune checkpoint represents a new inhibitory component of the known TIGIT axis at recent SITC Annual Meeting (NASDAQ:CGEN)
us.rd.yahoo.com - December 7 at 4:54 PM
finance.yahoo.com logoCompugen Announces Key Highlights from R&D Day (NASDAQ:CGEN)
finance.yahoo.com - December 7 at 4:54 PM
News IconRSI Update on Shares of Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - December 7 at 6:37 AM
finance.yahoo.com logoCompugen Appoints Senior Vice President Corporate and Business Development (NASDAQ:CGEN)
finance.yahoo.com - December 5 at 12:33 PM
News IconTechnical Trading Review on Shares of Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - December 3 at 8:07 AM
News IconFocus on RSI and CCI Levels: Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - November 30 at 7:53 AM
News IconStock Focus: Technical Levels in Review for Compugen Ltd. (CGEN) - MicroCap Wired (NASDAQ:CGEN)
www.microcapwired.com - November 24 at 12:03 PM
News IconTraders are Following Technical Levels for Compugen Ltd. (CGEN) - MicroCap Wired (NASDAQ:CGEN)
www.microcapwired.com - November 22 at 9:51 PM
News IconWhat are the Levels Showing for Shares of Compugen Ltd. (CGEN) - MicroCap Wired (NASDAQ:CGEN)
www.microcapwired.com - November 22 at 9:37 AM
capitalcube.com logoCompugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : November 22, 2016 (NASDAQ:CGEN)
www.capitalcube.com - November 22 at 9:37 AM
finance.yahoo.com logoCompugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York (NASDAQ:CGEN)
finance.yahoo.com - November 21 at 9:06 AM
News IconStock to Watch: Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - November 18 at 8:31 PM
News IconTrading Scope: Indicator Review for Compugen Ltd. (CGEN) - Yankee Analysts (NASDAQ:CGEN)
yankeeanalysts.com - November 18 at 1:23 PM

Social

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

Where is Compugen's stock going? Where will Compugen's stock price be in 2017?

3 brokers have issued twelve-month price objectives for Compugen's stock. Their forecasts range from $11.00 to $14.00. On average, they expect Compugen's stock price to reach $12.00 in the next twelve months.

What are analysts saying about Compugen stock?

Here are some recent quotes from research analysts about Compugen stock:

  • FBR & Co analysts commented, "On February 15, Compugen hosted a conference call to discuss its 4Q16 and FY16 results, and announced that it is searching for a new chairperson for its board of directors to replace its current Chairman Martin Gerstel. We consider the decision benign as Mr. Gerstel’s decision to step down is motivated by his wish to fill the chair with someone who is seasoned in clinical development and commercialization as CGEN draws near to filing its first IND and advancing its own investigational therapy into the clinic. While Mr. Gerstel has successfully led CGEN from using its unique target prediction technologies through discovery of multiple drug targets, we think this decision is logical as CGEN transforms into a clinical-stage company. We look for the first IND filing expected in 4Q17 to be a significant inflection point in the company’s valuation." (2/16/2017)

  • According to Zacks Investment Research, "Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen's expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. " (1/3/2017)

Who owns Compugen stock?

Compugen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Raging Capital Management LLC (6.15%), Renaissance Technologies LLC (1.05%), ARK Investment Management LLC (0.43%), Menta Capital LLC (0.30%) and Stockman Wealth Management Inc. (0.18%).

Who sold Compugen stock? Who is selling Compugen stock?

Compugen's stock was sold by a variety of institutional investors in the last quarter, including Raging Capital Management LLC, Menta Capital LLC and Stockman Wealth Management Inc..

Who bought Compugen stock? Who is buying Compugen stock?

Compugen's stock was bought by a variety of institutional investors in the last quarter, including ARK Investment Management LLC and Renaissance Technologies LLC.

How do I buy Compugen stock?

Shares of Compugen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Compugen stock cost?

One share of Compugen stock can currently be purchased for approximately $4.30.

Compugen (NASDAQ:CGEN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Compugen (NASDAQ:CGEN)

Earnings History Chart

Earnings by Quarter for Compugen (NASDAQ:CGEN)

Dividend History Chart

Dividend Payments by Quarter for Compugen (NASDAQ:CGEN)

Last Updated on 2/25/2017 by MarketBeat.com Staff